THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC)

Clinical trials for THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC) explained in plain language.

Never miss a new study

Get alerted when new THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC) trials appear

Sign up with your email to follow new studies for THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Long-Acting cancer drug seeks to boost immune system against tumors

Disease control Ongoing

This early-stage trial is testing a new long-acting immunotherapy drug called TransCon IL-2 β/γ in adults with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe doses and see if the drug, given alone or with other cancer treatment…

Matched conditions: THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC)

Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC)

Get alerted when new THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC) trials appear

New Long-Acting cancer drug seeks to boost immune system against tumors